# Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct05089734/  
OnCo record `nct05089734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab govitecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05089734 by Gilead Sciences, with 603 participants enrolled, started 2021-11-17 and due to reach its primary completion in 2023-11-29. Interventions recorded: Sacituzumab Govitecan-hziy (SG), Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05089734
- Phase: 3
- Setting: Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Sponsor: Gilead Sciences
- Enrolled: 603

## Sources

- ClinicalTrials.gov NCT05089734: https://clinicaltrials.gov/study/NCT05089734

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05089734.json